SEARCH

SEARCH BY CITATION

References

  • 1
    Bronte, V. and Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005. 5: 641654.
  • 2
    Gabrilovich, D. I. and Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009. 9: 162174.
  • 3
    Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M. and Kast, W. M., Mechanism of immune dysfunction in cancer mediated by immature Gr-1+myeloid cells. J. Immunol. 2001. 166: 53985406.
  • 4
    Pericle, F., Kirken, R. A., Bronte, V., Sconocchia, G., DaSilva, L. and Segal, D. M., Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J. Immunol. 1997. 159: 25802585.
  • 5
    Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P. and Restifo, N. P., Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 1999. 162: 57285737.
  • 6
    Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P. and Zanovello, P., Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000. 96: 38383846.
  • 7
    Kusmartsev, S. A., Li, Y. and Chen, S. H., Gr-1+myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 2000. 165: 779785.
  • 8
    Liu, C., Yu, S., Kappes, J., Wang, J., Grizzle, W. E., Zinn, K. R. and Zhang, H. G., Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007. 109: 43364342.
  • 9
    Gallina, G., Dolcetti, L., Serafini, P., De Santo, C., Marigo, I., Colombo, M. P., Basso, G. et al., Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 2006. 116: 27772790.
  • 10
    Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D. and Ostrand-Rosenberg, S., Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 2009. 183: 937944.
  • 11
    Nagaraj, S., Collazo, M., Corzo, C. A., Youn, J. I., Ortiz, M., Quiceno, D. and Gabrilovich, D. I., Regulatory myeloid suppressor cells in health and disease. Cancer Res. 2009. 69: 75037506.
  • 12
    Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A. et al., Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004. 64: 58395849.
  • 13
    Makarenkova, V. P., Bansal, V., Matta, B. M., Perez, L. A. and Ochoa, J. B., CD11b+/Gr-1+myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 2006. 176: 20852094.
  • 14
    Delano, M. J., Scumpia, P. O., Weinstein, J. S., Coco, D., Nagaraj, S., Kelly-Scumpia, K. M., O'Malley, K. A. et al., MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007. 204: 14631474.
  • 15
    Dugast, A. S., Haudebourg, T., Coulon, F., Heslan, M., Haspot, F., Poirier, N., Vuillefroy de Silly, R. et al., Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J. Immunol. 2008. 180: 78987906.
  • 16
    Haile, L. A., von Wasielewski, R., Gamrekelashvili, J., Kruger, C., Bachmann, O., Westendorf, A. M., Buer, J. et al., Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008. 135: 871881, 881 e871–e875.
  • 17
    Klein, T. W., Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005. 5: 400411.
  • 18
    Klein, T. W., Friedman, H. and Specter, S., Marijuana, immunity and infection. J. Neuroimmunol. 1998. 83: 102115.
  • 19
    McKallip, R. J., Lombard, C., Martin, B. R., Nagarkatti, M. and Nagarkatti, P. S., Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. 2002. 302: 451465.
  • 20
    Zhu, W., Friedman, H. and Klein, T. W., Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J. Pharmacol. Exp. Ther. 1998. 286: 11031109.
  • 21
    Jia, W., Hegde, V. L., Singh, N. P., Sisco, D., Grant, S., Nagarkatti, M. and Nagarkatti, P. S., Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol. Cancer Res. 2006. 4: 549562.
  • 22
    Do, Y., McKallip, R. J., Nagarkatti, M. and Nagarkatti, P. S., Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 2004. 173: 23732382.
  • 23
    Hegde, V. L., Hegde, S., Cravatt, B. F., Hofseth, L. J., Nagarkatti, M. and Nagarkatti, P. S., Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol. 2008. 74: 2033.
  • 24
    Klein, T. W., Lane, B., Newton, C. A. and Friedman, H., The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 2000. 225: 18.
  • 25
    Greifenberg, V., Ribechini, E., Rossner, S. and Lutz, M. B., Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 2009. 39: 28652876.
  • 26
    De Wilde, V., Van Rompaey, N., Hill, M., Lebrun, J. F., Lemaitre, P., Lhomme, F., Kubjak, C. et al., Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am. J. Transplant. 2009. 9: 20342047.
  • 27
    Vaknin, I., Blinder, L., Wang, L., Gazit, R., Shapira, E., Genina, O., Pines, M. et al., A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood 2008. 111: 14371447.
  • 28
    Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., Geilich, M. et al., Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 2010. 40: 2235.
  • 29
    Hock, H., Hamblen, M. J., Rooke, H. M., Traver, D., Bronson, R. T., Cameron, S. and Orkin, S. H., Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 2003. 18: 109120.
  • 30
    Youn, J. I., Nagaraj, S., Collazo, M. and Gabrilovich, D. I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008. 181: 57915802.
  • 31
    Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P. and Van Ginderachter, J. A., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008. 111: 42334244.
  • 32
    Ostrand-Rosenberg, S. and Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009. 182: 44994506.
  • 33
    Bunt, S. K., Sinha, P., Clements, V. K., Leips, J. and Ostrand-Rosenberg, S., Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006. 176: 284290.
  • 34
    Klein, T. W., Newton, C. A., Nakachi, N. and Friedman, H., Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J. Immunol. 2000. 164: 64616466.
  • 35
    Metcalf, D., The granulocyte-macrophage colony-stimulating factors. Science 1985. 229: 1622.
  • 36
    Murata, A., Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis. Curr. Pharm. Des. 2003. 9: 11151120.
  • 37
    Abe, F., Dafferner, A. J., Donkor, M., Westphal, S. N., Scholar, E. M., Solheim, J. C., Singh, R. K. et al., Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol. Immunother. 2010. 59: 4762.
  • 38
    Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J. E., Abe, J., Shono, Y. et al., Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008. 111: 54575466.
  • 39
    Berdyshev, E. V., Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 2000. 108: 169190.
  • 40
    Weiss, M., Moldawer, L. L. and Schneider, E. M., Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 1999. 93: 425439.
  • 41
    Reagan-Shaw, S., Nihal, M. and Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 2008. 22: 659661.
  • 42
    Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. and Bucher, J. R., Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam. Appl. Toxicol. 1996. 30: 109117.
  • 43
    Azorlosa, J. L., Heishman, S. J., Stitzer, M. L. and Mahaffey, J. M., Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J. Pharmacol. Exp. Ther. 1992. 261: 114122.
  • 44
    Johansson, E., Noren, K., Sjovall, J. and Halldin, M. M., Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed. Chromatogr. 1989. 3: 3538.
  • 45
    McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S. and Nagarkatti, M., Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002. 100: 627634.
  • 46
    McKallip, R. J., Nagarkatti, M. and Nagarkatti, P. S., Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 2005. 174: 32813289.
  • 47
    Hashibe, M., Ford, D. E. and Zhang, Z. F., Marijuana smoking and head and neck cancer. J. Clin. Pharmacol. 2002. 42: 103S107S.
  • 48
    Chacko, J. A., Heiner, J. G., Siu, W., Macy, M. and Terris, M. K., Association between marijuana use and transitional cell carcinoma. Urology 2006. 67: 100104.
  • 49
    Sinha, P., Clements, V. K., Fulton, A. M. and Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007. 67: 45074513.
  • 50
    Pertwee, R. G., Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009. 156: 397411.